Regencell Bioscience (NASDAQ:RGC) Shares Up 5.5% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price shot up 5.5% on Wednesday . The company traded as high as $6.75 and last traded at $6.2780. 160,941 shares were traded during mid-day trading, a decline of 48% from the average daily volume of 312,093 shares. The stock had previously closed at $5.95.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Regencell Bioscience Stock Up 24.6%

The firm has a fifty day simple moving average of $20.01 and a 200-day simple moving average of $25.09.

Regencell Bioscience (NASDAQ:RGC) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.00) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in shares of Regencell Bioscience in the fourth quarter valued at approximately $92,000. Amundi acquired a new stake in shares of Regencell Bioscience during the first quarter worth $219,000. Vident Advisory LLC lifted its position in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after acquiring an additional 11,866 shares in the last quarter. Hudson Bay Capital Management LP bought a new stake in Regencell Bioscience in the 4th quarter valued at $275,000. Finally, Bank of America Corp DE boosted its stake in Regencell Bioscience by 59,113.8% in the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the period. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.